Evidence map›Paper›PMID 38247820›Full record

ArticleCells2024

Development of Innate-Immune-Cell-Based Immunotherapy for Adult T-Cell Leukemia-Lymphoma.

Maho Nakashima, Yoshimasa Tanaka, Haruki Okamura, Takeharu Kato, Yoshitaka Imaizumi, Kazuhiro Nagai, Yasushi Miyazaki, Hiroyuki Murota

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Maho NakashimaDepartment of Dermatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan.
Yoshimasa TanakaCenter for Medical Innovation, Nagasaki University, Nagasaki 852-8588, Japan.ORCID 0000-0002-5024-0614
Haruki OkamuraDepartment of Tumor Cell Therapy, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.
Takeharu KatoDepartment of Hematology, Nagasaki University Hospital, Nagasaki 852-8501, Japan.
Yoshitaka ImaizumiDepartment of Hematology, National Hospital Organization Nagasaki Medical Center, Omura 856-8562, Japan.
Kazuhiro NagaiDepartment of Clinical Laboratory, National Hospital Organization Nagasaki Medical Center, Omura 856-8562, Japan.
Yasushi MiyazakiDepartment of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, Japan.
Hiroyuki MurotaDepartment of Dermatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan.
Nagasaki University · JPNagasaki Medical Center · JPHyogo Medical University · JPNagasaki University Hospital · JP

Funding

JST START University Ecosystem Promotion Type (Supporting Creation of Startup Ecosystem in Startup Cities), Japan, to YT, Grants-in-Aid for Scientific Research from MEXT to YT, Grants-in-Aid for Scientific Research from Japan Agency for Medical Research a JPMJST2281, 16K08844 and 23K06677, A48 and A90
6 · The paper itself

Abstract

γδ T cells and natural killer (NK) cells have attracted much attention as promising effector cell subsets for adoptive transfer for use in the treatment of malignant and infectious diseases, because they exhibit potent cytotoxic activity against a variety of malignant tumors, as well as virus-infected cells, in a major histocompatibility complex (MHC)-unrestricted manner. In addition, γδ T cells and NK cells express a high level of CD16, a receptor required for antibody-dependent cellular cytotoxicity. Adult T-cell leukemia-lymphoma (ATL) is caused by human T-lymphotropic virus type I (HTLV-1) and is characterized by the proliferation of malignant peripheral CD4

Indexed as

Human T-lymphotropic virus 1Leukemia-Lymphoma, Adult T-CellAdultAgedAntibodies, MonoclonalHumansImmunotherapyInterleukin-18Interleukin-2Leukocytes, MononuclearAntibodies, MonoclonalInterleukin-18Interleukin-2adult T-cell leukemia–lymphomainfusion therapyinterleukin-18interleukin-2nitrogen-containing bisphosphonate prodrugNK cellγδ T cell

Identifiers

PMID38247820
PMCPMC10814776
OpenAlexW4390696054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.